Shrink Nanotechnologies Expands Scientific Advisory Board with the Appointment of Two Leading Biotechnology Research Experts

Company Progressing Toward Commercialization of its StemDisc and CellAlign
Technologies
CARLSBAD, Calif.--(Business Wire)--
Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative
nanotechnology company developing products and licensing opportunities in the
solar energy production, medical diagnostics and sensors and biotechnology
research and development tools businesses, today announced that Bruce R.
Conklin, M.D., a Senior Investigator at the Gladstone Institute and Professor of
Medical Genetics and Cellular and Molecular Pharmacology at the University of
California San Francisco, and Dr. Kara McCloskey, Professor at the School of
Engineering, University of California, Merced, have joined its Scientific
Advisory Board (SAB).

Drs. Conklin and McCloskey, respectively, bring their IPS (or induced
pluripotent stem cell) and tissue engineering expertise to the Shrink`s suite of
biotechnology research tools, StemDisc and CellAlign. Dr. Conklin in particular
is a recognized international leader in the movement to use stem cells to
discover cutting-edge drugs and to eventually use stem cell research to create
therapies to cure disease. These important additions further strengthen the SAB,
which already includes Dr. Michelle Khine, the scientific founder of Shrink`s
nanofabrication platform.

"We are extremely honored to have these two distinguished scientists join our
advisory board. The Scientific Advisory Board plays a key role in keeping Shrink
closely associated with the scientific community and provides both scientific
and industry guidance to our evolving technologies, supporting our company
mandate, which is to bring these technologies to commercialization," said Mark
L. Baum, CEO of Shrink Nanotechnologies. "Shrink now has an exceptional group of
scientific advisors who bring complementary skills and expertise to our novel
biological research and development tools."

Shrink is developing biological research and development tools that employ its
technology and microfabrication expertise to offer a new paradigm for cell
biology, molecular biology, immunodiagnostics and stem cell research.

Shrink`s current products include:

StemDisc, designed to improve embryoid body (EB) formation of stem cells at a
higher rate and efficiency over current EB formation methods. It also allows for
a multitude of applications across many currently existing microwell plate
formats, thereby increasing the flexibility of use for researchers.

CellAlign, a platform technology that allows for the structured alignment of
biological tissues, particularly tissues which naturally grow in a linear
fashion--cardiac or nerve tissue. The key feature is a microfabricated substrate
with non-periodic linear patterned grooves that allow for the alignment of cells
along a single axis. One such potential use for CellAlign is the creation of
"heart patches" for the treatment of damaged heart tissue during cardiac
infarction.

Scientific Advisory Board Member Biographies

Bruce R. Conklin, MD, is a Senior Investigator at the Gladstone Institute of
Cardiovascular Disease and a Professor at the University of California, San
Francisco, with appointments in the Departments of Medicine and Cellular and
Molecular Pharmacology. His research combines genetic techniques and
bioinformatics to study G-Protein Couple Receptor hormone signaling involved in
murine embryonic stem cells (mESC) and pluripotent embryonic stem (ES) cells.
The cell lines can be used in to analyze toxic side effects of pharmaceuticals
and study the differentiation of embryonic stem cells into cardiac tissues. Dr.
Conklin served as the founding director of the Gladstone Genomics Core and is
currently the founding director of the Gladstone Stem Cell Core. From 1995 to
2001, Dr. Conklin was the Associate Director of the General Clinical Research
Center at San Francisco General Hospital. He is a member of several honorary
societies including the American Society for Clinical Investigation. Dr. Conklin
was the co-chair of the UCSF public science project in 1994, and is co-chair of
the UCSF-California Academy of Sciences Affiliation Task Force. Dr. Conklin is
the Associate Director of the Gladstone CIRM Scholars Training Program, and the
recipient of a CIRM New Stem Cell Lines grant. Dr. Conklin is a key advisor to
iPierian, Inc., a Kleiner Perkins-backed biopharmaceutical company located in
San Francisco.

Kara McCloskey, PhD, is Professor at School of Engineering, University of
California, Merced. She is a chemical engineer who applies standard engineering
principles, such as analysis and design, to the field of stem cells and tissue
engineering. She has conducted significant research in the field of tissue
engineering with a specific focus on the cardiovascular system and stem cells.
She has co-authored numerous articles on stem cells and cell properties.

For further information on Shrink Nanotechnologies, StemDisc and CellAlign, and
to be kept updated on company announcements, please visit
http://www.shrinknano.com/rdbio.php and sign up for the Shrink Technology
newsletter.

About Shrink Nanotechnologies, Inc.

Shrink is a first-of-its-kind FIGA organization. FIGA companies are "for profit"
businesses that bring together diverse contributions from leaders in the worlds
of finance, industry, government and academia. Shrink`s solutions, including its
diverse polymer substrates, nano-devices and biotech research tools, among
others, are designed to be ultra-functional and mechanically superior in the
solar energy, environmental detection, stem cell and biotechnology markets.
Shrink has created the ShrinkChip Manufacturing Solution which utilizes the
unique characteristics of NanoShrink, Shrink`s core multi-grade plastic
material. Made from a unique shrinkable thermo-plastic material, NanoShrink
enable complex ultra-functional nano-structures to be designed at the
macro-scale and shrunken down, while retaining the original designs on a much
smaller nano scale. This flexible and elegant design and fabrication solution
reduces costs by eliminating the need for expensive clean room equipment, vastly
improving time-to-market for products in Shrink`s focused market segments.

Brainerd Communicators
Scott Cianciulli, 212-986-6667
Cianciulli@braincomm.com

Copyright Business Wire 2009